Last updated: 3 August 2023 at 8:27pm EST

Bio Venture Partners Fund I... Net Worth




The estimated Net Worth of Bio Venture Partners Fund I... is at least 8.19 百万$ dollars as of 1 August 2023. Bio I owns over 833,333 units of Inozyme Pharma stock worth over 8,188,771$ and over the last 6 years Bio sold INZY stock worth over 0$.

Bio I INZY stock SEC Form 4 insiders trading

Bio has made over 4 trades of the Inozyme Pharma stock since 2018, according to the Form 4 filled with the SEC. Most recently Bio bought 833,333 units of INZY stock worth 3,999,998$ on 1 August 2023.

The largest trade Bio's ever made was buying 1,070,000 units of Inozyme Pharma stock on 19 April 2022 worth over 3,948,300$. On average, Bio trades about 607,139 units every 442 days since 2018. As of 1 August 2023 Bio still owns at least 1,571,741 units of Inozyme Pharma stock.

You can see the complete history of Bio I stock trades at the bottom of the page.



What's Bio I's mailing address?

Bio's mailing address filed with the SEC is 1700 Owens St, San Francisco, CA 94158, USA.

Insiders trading at Inozyme Pharma

Over the last 4 years, insiders at Inozyme Pharma have traded over 0$ worth of Inozyme Pharma stock and bought 11,149,230 units worth 104,131,475$ . The most active insiders traders include Forest BaskettScott D SandellAnthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of 2,019,505$. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth 130,250$.



What does Inozyme Pharma do?

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.



Complete history of Bio I stock trades at Entasis Therapeutics Inc、Inozyme Pharma

インサイダー
取引
取引
合計金額
Bio Venture Partners Fund I...
購入する 3,999,998$
1 Aug 2023
Bio Venture Partners Fund I...
購入する 3,948,300$
19 Apr 2022
Bio Venture Partners Fund I...
購入する 3,000,000$
28 Jul 2020
Bio Venture Partners Fund I...
購入する 5,065,860$
28 Sep 2018


Inozyme Pharma executives and stock owners

Inozyme Pharma executives and other stock owners filed with the SEC include: